Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R21/Matrix-M Malaria Vaccine in Kenyan Adults, Children, and Infants
NCT03580824Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Apr 2019
- Primary completion
- Jun 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of R21/Matrix-M in malaria, sponsored by University of Oxford. Started Apr 2019; status: completed.
02
Drugs
R21/Matrix-M
03
Conditions
malaria
Beyond the preview
Go deeper on NCT03580824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03580824.